Trial Profile
A Randomized, Parallel-group, Double-blind and Open-label Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Vilaprisan (Primary)
- Indications Uterine leiomyoma
- Focus Registrational; Therapeutic Use
- Acronyms ASTEROID 3
- Sponsors Bayer
- 05 May 2023 Status changed from completed to discontinued.
- 17 May 2022 Status changed from active, no longer recruiting to completed.
- 01 Mar 2022 Planned End Date changed from 28 Feb 2022 to 30 Apr 2022.